A detailed history of Cherry Creek Investment Advisors, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Cherry Creek Investment Advisors, Inc. holds 5,260 shares of GILD stock, worth $474,399. This represents 0.23% of its overall portfolio holdings.

Number of Shares
5,260
Previous 4,943 6.41%
Holding current value
$474,399
Previous $339,000 29.79%
% of portfolio
0.23%
Previous 0.18%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 22, 2024

BUY
$66.59 - $83.99 $21,109 - $26,624
317 Added 6.41%
5,260 $440,000
Q2 2024

Jul 17, 2024

SELL
$63.15 - $72.88 $111,207 - $128,341
-1,761 Reduced 26.27%
4,943 $339,000
Q1 2024

Apr 23, 2024

SELL
$71.58 - $87.29 $5,654 - $6,895
-79 Reduced 1.16%
6,704 $491,000
Q4 2023

Jan 26, 2024

BUY
$73.27 - $83.09 $3,956 - $4,486
54 Added 0.8%
6,783 $549,000
Q3 2023

Oct 13, 2023

BUY
$73.94 - $80.67 $4,288 - $4,678
58 Added 0.87%
6,729 $504,000
Q2 2023

Jul 14, 2023

BUY
$76.01 - $86.7 $17,558 - $20,027
231 Added 3.59%
6,671 $514,000
Q1 2023

Apr 24, 2023

SELL
$77.31 - $88.08 $20,564 - $23,429
-266 Reduced 3.97%
6,440 $534,000
Q4 2022

Feb 10, 2023

SELL
$62.32 - $89.47 $2,679 - $3,847
-43 Reduced 0.64%
6,706 $575,000
Q3 2022

Oct 24, 2022

BUY
$59.54 - $68.01 $4,405 - $5,032
74 Added 1.11%
6,749 $416,000
Q2 2022

Jul 20, 2022

BUY
$57.72 - $65.01 $12,525 - $14,107
217 Added 3.36%
6,675 $413,000
Q1 2022

Apr 22, 2022

BUY
$57.92 - $72.58 $42,223 - $52,910
729 Added 12.72%
6,458 $384,000
Q4 2021

Feb 11, 2022

BUY
$64.88 - $73.64 $66,631 - $75,628
1,027 Added 21.84%
5,729 $416,000
Q3 2021

Nov 01, 2021

BUY
$67.69 - $73.03 $8,935 - $9,639
132 Added 2.89%
4,702 $328,000
Q2 2021

Aug 13, 2021

BUY
$63.47 - $69.35 $290,057 - $316,929
4,570 New
4,570 $314,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $113B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Cherry Creek Investment Advisors, Inc. Portfolio

Follow Cherry Creek Investment Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cherry Creek Investment Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cherry Creek Investment Advisors, Inc. with notifications on news.